Curriculum Vitae

Transmissible Spongiform Encephalopathies Advisory Committee


Name: Susan F. Leitman, M.D.
Office Address:

Department of Transfusion Medicine
National Institutes of Health
Building 10, Room lC-711
9000 Rockville Pike
Bethesda, Maryland 20892

Current Positions

 1985 - present

Chief, Blood Services Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD
1992 - present Deputy Chief, Department of Transfusion Medicine
National Institutes of Health, Bethesda, MD

Education:

 -----------

B.A., Brown University
----------- M.D., Brown University Program In Medicine

Postdoctoral Training:

 1977 - 78

Intern in Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
1978 - 80

Resident in Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
1980 - 83 Fellow in Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
1983 - 85 Senior Staff Fellow, Clinical Center Blood Bank
National Institutes of Health, Bethesda, Maryland
Current and Past Boards, Committees and Other Positions: 2004 – present

Co-Chair, Working Committee on Donor Health and Safety, Center for International Blood and Marrow Transplant Registry (CIBMTR)
2004 - present

Board of Tutors, Clinical Research Training Program, NIH
2003 - 2005

Vice-Chair, Board of Directors, National Marrow Donor Program

2003 - present

Member, Standards Committee, National Marrow Donor Program

2003 - 2005

Member, Strategic Planning Committee, National Marrow Donor Program

2002 - present

Member, Transmissible Spongiform Encephalopathies Committee, Center for Biologics Evaluation and Research, FDA
1998 - present

Ad Hoc Member, Blood Products Advisory Committee, Center for Biologics Evaluation and Research, FDA

1996 - 2002

Ad Hoc Member, Biologic Response Modifier Advisory Committee, Center for Biologics Evaluation and Research, FDA
1998 - 1999

Council President, National Marrow Donor Program
1996 - present

Member, Board of Directors, National Marrow Donor Program

1996 - 1998

Vice President for Donor Centers, National Marrow Donor Program
1995 - 2005

Member, NIH Clinical Center Promotion and Tenure Committee
1995 - 1998

Member, NIH Clinical Center Technology Development Committee
1994 - 1996

Member, Scientific Program Committee
American Association of Blood Banks
1993 - 1997

Member, Blood Products Advisory Committee Center for Biologics Evaluation and Research, FDA
1992 - 1998

Member (Chair 1996-1998), Donor and Patient Safety Monitoring Committee, National Marrow Donor Program
1991 - 1993

Member, Transfusion Practice Quality Assurance Committee
American Association of Blood Banks
1989 - 1994

Co-Chair, Scientific Program Committee
Mid-Atlantic Association of Blood Banks
1988 - 1994

Member, Clinical Applications Committee American Society for Apheresis

1987 - 1994

Member (Chair 1990-1994), Hemapheresis Committee
American Association of Blood Banks

Certification:

 1990 Pediatric Internship and Residency
1993 Children's Hospital of Pittsburgh
1994 Pittsburgh, Pennsylvania
1984 - 1986 Neonatology Fellowship
Babies Hospital
Columbia-Presbyterian Medical Center
New York, New York
1986 - 1988 Pediatric Infectious Diseases Fellowship
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
Medical License:

--------------- Commonwealth of Pennsylvania

Awards and Honors:

1974 Phi Beta Kappa
1974

Sigma Xi

1982

PHS National Research Service Award
1986 NIH Special Achievement Award
1991 Arthur S. Flemming Award, Scientific Division
1997

Charles E. Walter Memorial Award, Mid-Atlantic Association of Blood Banks

1999 NIH Distinguished Clinical Teacher Award
2004

NIHClinical Center Director’s Award
2004 Iron Disorders Institute "Making a Difference" Award

Membership in Professional and Scientific Societies:

American Society of Hematology

American Association of Blood Banks
American Society for Apheresis
Mid-Atlantic Association of Blood Banks
National Marrow Donor Program

Original Papers

  1. Anaclerio A, Leitman S, Galliette R, Heppner G, Calabresi P: Stimulatory effects of 5-iodo-2'-deoxyuridine on number and function of splenic T-cells and of macrophages in C3HeB/FeJ mice. Cancer Research 36:73-76, 1976.
  2. Bennett JS, Hoxie JA, Leitman SF, Vilaire G, Cines, DB: Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci, USA 80:2417-2421, 1983.
  3. Leitman SF, and Holland PV: Irradiation of blood products: Indications and guidelines. Transfusion 25:293-300, 1985.
  4. Rosenberg SA, Lotze MT, Muul LM, Leitman SF, Chang AE, Ettinghausen SE, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985.
  5. Klein HG, Balow JE, Dau PC, Hamburger MI, Leitman SF, Pineda AA, Tindall RS: Clinical applications of therapeutic apheresis: report of the Clinical Applications Committee, American Society for Apheresis. J Clin Apheresis 3:15-16, 21-22, 39-40, 43-44, 1986.
  6. Rosenberg SA, Lotze MT, Muul LM, Leitman SF, Chang AE, Vetto JT, et al: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 100:262-270, 1986.
  7. Leitman SF, Boltansky H, Alter HJ, Pearson FC, Kaliner MA: Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. N Engl J Med 15:1192-1196, 1986.
  8. Stevenson HC, Stevenson GW, Leitman SF, Carter CS, Alvord G, Klein HG: The isolation of human mononuclear leukocyte subsets by cytapheresis for laboratory research. Plasma Ther Transfus Technol 7:365-371, 1986.
  9. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman SF, et al: Clinical experience with treatment of 157 patients with advanced cancer using lymphokine-¬activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889-897, 1987.
  10. Carter CS, Leitman SF, Cullis H, Muul LM, Rosenberg SA, Klein HG: Use of a continuous-flow cell separator in density gradient isolation of lymphocytes. Transfusion 27:362-365, 987.
  11. Muul LM, Carter CS, Cullis H, Leitman SF, Klein HG, Rosenberg SA, et al: Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. J Immunolog Methods 101:171-181, 1987.
  12. Adde MA, Leitman SF: Nursing considerations in the clinical management of patients undergoing selective removal of LDL using secondary membrane filtration: J Clin Apheresis 4:82-84, 1988.
  13. Carter CS, Leitman SF, Cullis H, Muul LM, Rosenberg SA, Klein HG: Technical aspects of lymphokine-activated killer cell production. J Clin Apheresis 4:113-117, 1988.
  14. Aebersold P, Carter CS, Hyatt C, Johnson S, Leitman SF, Rosenberg SA: A simplified procedure for generation of human lymphokine-activated killer cells for use in clinical trials. J Immunolog Methods 112:1-7, 1988.
  15. Read EJ, Kodis C, Carter CS, Leitman SF: In vivo survival of platelets following storage in the irradiated state: A pair-controlled study. Transfusion 28:446-450, 1988.
  16. Klein HG, Leitman, SF: Adoptive immunotherapy in the treat¬ment of malignant disease. Transfusion 29:170-178, 1989.
  17. DePalma L, Leitman SF, Carter CS, Gallin JI: Granulocyte transfusion therapy in a child with chronic granulomatous disease and multiple red cell alloantibodies. Transfusion 29:421-423, 1989.
  18. Leitman SF, Smith J, Gregg RE: Homozygous familial hypercholesterolemia: selective removal of low density lipoproteins by secondary membrane filtration. Transfusion 29:341-346, 1989.
  19. Leitman SF, Klein HG, Melpolder JJ, Read EJ, Esteban JI, Leonard EM, Harvath L, Shih JWK, Nealon R, Foy J, Darr F, Alter HJ: Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med 321:917-924, 1989.
  20. Leitman SF: Use of blood cell irradiation in the prevention of posttransfusion graft-versus-host disease. Transfusion Science 10:219-232, 1989.
  21. Loiacono B, Carter GR, Carter CS, Leitman SF, Klein HG: Efficacy of various methods of confidential unit exclusion in identifying potentially infectious blood donations. Transfusion 29:823-826, 1989.
  22. DePalma L, Palmer R, Leitman SF, Dolan WD, Klein HG: Utilization patterns of frozen autologous red blood cells; experience in a referral center and a community hospital. Arch Pathol Lab Med 114:516-518, 1990.
  23. Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman SF, Klein HG, Steis RG, Longo DL, Fauci AS: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 113:512-519, 1990.
  24. DePalma L, Criss VR, Sullivan MT, Leitman SF, Williams AE, Luban NLC: Detection of cytomegalovirus antibody in platelet concentrates by fluorescent immunoassay and latex agglutination. Transfusion 31:245-248, 1991.
  25. Shih JWK, Kung K, Pottathil R, Leitman SF, Klein HG, Melpolder JJ, Alter HJ: Quantitative analysis of an HIV positive blood donor cohort. In: Andrieu, JM, ed. Viral quantitation in HIV infection. John Libbey Eurotext, Paris. P. 171-176, 1991.
  26. Shirai A, Cosentino M, Leitman SF, Klinman DM: Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 89:561-566, 1992.
  27. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326:1380-1384, 1992.
  28. Davey RJ, McCoy NC, Yu M, Sullivan JA, Spiegel DM, Leitman SF: The effect of prestorage irradiation on posttransfusion red cell survival. Transfusion 32:525-528, 1992.
  29. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM, Illingworth DR, Jones PH, Leitman SF, Stein EA, Stern TN, Zavoral JH, Zweiner J: Multicenter controlled study of the treatment of refractory familial hypercholesterolemia by LDL-apheresis using the Liposorber LA-15 System. Am J Cardiol 70:1010-1016, 1992.
  30. Suda BA, Leitman SF, Davey RJ: Characteristics of red cells irradiated and subsequently frozen for long term storage. Transfusion 33:389-392, 1993.
  31. Leitman SF. Dose, dosimetry, and the quality control of irradiated blood components. (Editorial). Transfusion 33:447-449, 1993.
  32. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang FE, Aebersold P, Leitman SF, Linehan WM, Steinberg SM. Prospective randomized trial of high dose interleukin-2 alone or nconjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-632, 1993.
  33. Pockaj BA, Sherry R, Yanelli JR, Carter CS, Leitman SF, Carrasquillo JR, Rosenberg SA, Yang JC. Localization of 111Indium-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 73:1731-1737, 1994.
  34. Stehling L, Luban NLC, Anderson KC, Sayers MH, Long A, Attar S, Leitman SF, Gould SA, Kruskall MS, Goodnough LT, Hines DM. Guidelines for blood utilization review. Transfusion 34:438-448, 1994.
  35. Cole DJ, Taubenberger JK, Pockaj BA, Yanelli JR, Carter CS, Carasquillo J, Leitman SF, Steinberg SM, Rosenberg SA, Yang JC. Histopathologic analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor infiltrating lymphocytes. Cancer Immunol Immunother 38:299-303, 1994.
  36. O'Shaughnessey JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Fox MC, Leitman SF, Gottesman M, Pastan I, Gress R. Clinical Protocol: Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Human Gene Therapy 5:891-911, 1994.
  37. Lekstrom JA, Holland SM, DeCarlo ES, Miller J, Leitman SF, Chang R, Baker AR, Gallin JI. Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscesses. J Clin Infect Dis 19:770-773, 1994.
  38. Cosentino M, Leitman SF, Klinman DM. HIV-specific B cells localize to the bone marrow of gp160-immunized mice and humans. Vaccine Research 3:195-199, 1994.
  39. Chen CC, Kerr GS, Carter CS, Read EJ, Carrasquillo JA, Leitman SF, Hoffman GS. Lack of sensitivity of indium-111 mixed leukocyte scans for active disease in Takayasu's Arteritis. Am J Rheumatol 22:478-481, 1995.
  40. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter CS, Berenson R, Brown S, Greenblatt J, Stewart F M, Leitman SF, Wilson WH, Cowan K, Young NS, Nienhuis AW. Retrovirally-marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85:3048-3057, 1995.
  41. Lee JH, Leitman SF, Klein HG. A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collection by centrifugal leukapheresis. Blood 86:4662-4666, 1995.
  42. Lee JH, Cullis H, Leitman SF, Klein HG. The efficacy of pentastarch in granulocyte collection by centrifugal leukapheresis. Journal of Clinical Apheresis 10:198-202, 1995.
  43. Hagiwara E, Sacks T, Leitman SF, Klinman DM. Effect of HIV infection on the frequency of cytokine-secreting cells in human peripheral blood. AIDS Research and Human Retroviruses 12:127-131, 1996.
  44. Sekhsaria S, Fleisher TA, Vowells S, Brown M, Miller J, Gordon I, Blaese MR, Dunbar CE, Leitman SF, Malech HL. Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase-deficient SCID patients. Blood 88:1104-1112, 1996.
  45. Leitman SF, Read EJ. Hematopoietic Progenitor Cells. In: Klein HG (editor). Transfusion Medicine. Sem Hematol 33:341-358, 1996.
  46. Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman SF. Alloimmunization after granulocyte transfusions. Transfusion 36:1009-1015, 1996.
  47. Malech HL, Maples PB, Whiting-Theobald N, Linton G F, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Maack CA, Rokovich JA, Cohen LK, Gallin JI. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94, 12133-12138, 1997.
  48. Emmons RVB, Doren S, Zujewski J, Cottler-Fox M, Carter CS, O’Shaughnessy JA, Leitman SF, Greenblatt JJ, Cowan K, Dunbar CE. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood 89:4040-4046, 1997.
  49. Moroff G, Leitman SF, Luban NLC. Principles of blood irradiation, dose validation and quality control. Transfusion 37:1084-1092, 1997.
  50. Brady RO, Murray GJ, Leitman SF, Sneller MC, Fleisher TA, Barton NW. Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. Pediatrics 100:E11, 1997.
  51. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman SF, Horowitz M, Gluckman E, Rowley S, Przepiorka D, Champlin R. Allogeneic blood stem cell transplantation: considerations for donors. Blood 90:903-908, 1997.
  52. Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin JA, Pensiero M, Long Z, Lockey C, Emmons RV, Csik S, Leitman SF, Krebs CB, Carter C, Brady RO, Karlsson S. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 9:2629-40, 1998.
  53. Gordon BR, Kelsey SF, Dau, PC, Gotto AM, Graham K, Illingworth R, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stein EA, Stern TN, Troendle A, Zweiner RJ. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 81:407-411, 1998.
  54. Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration in HIV-infected adults. Nat Med 4:852-856, 1998.
  55. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352:866-870, 1998.
  56. Stroncek DS, Leitman SF. Granulocyte transfusions: a review. Immunohematology 14:101-108, 1998.
  57. Dunbar C, Chang L, Mullen C, Ramsey WJ, Carter C, Kohn D, Parkman R, Lenarsky C, Weinberg K, Wara D, Culver KW, Anderson WF, Leitman SF, Fleisher T, Klein H, Shearer G, Clerici M, McGarrity G, Bastian J, Hershfield MS. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene. Hum Gene Ther 10:477-8, 1999.
  58. Goedert JJ, Sauter ME, Jacobson LP, Vessella RL, Hilgartner MW, Leitman SF, Fraser MC, Mueller-Lantzsch NG. High prevalence of antibodies against HERV-K10 in patients with testicular cancer but not with AIDS. Cancer Epidemiol Biomarkers Prev 8:293-6, 1999.
  59. Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene(FANCC). Human Gene Ther 10:2337-2346, 1999.
  60. Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 5:1619-28, 1999.
  61. Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, Chow C, Venzon D, Sorrentino B, Chiang Y, Goldspiel B, Leitman SF, Read EJ, Abati A, Gottesman MM, Pastan I, Sellers S, Dunbar C, Cowan KH. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 94:52-61, 1999.
  62. Bolan CD, Leitman SF. Hematopoietic stem-cell transplantation for acute leukemia. N Engl J Med. 340:810, 1999 (letter).
  63. Childs R, Clave E, Contentin N, Hensel N, Leitman SF, Read EJ, Carter S, Bahceci E, Young NS, Barrett AJ. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234-3241, 1999.
  64. Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Effects of therapeutic plasma exchange and intravenous immunoglobulin for childhood-onset obsessive-compulsive disorder and tic disorders. Lancet 354:1153-1158, 1999.
  65. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin L, Huppi K, Chanock SJ. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 94:4220-4232, 1999.
  66. Bahceci E, Read EJ, Leitman SF, Childs R, Dunbar C, Young NS, Barrett AJ. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation for haematological malignancies. Br J Haematol 108:408-14, 2000.
  67. Stroncek DF, Confer DL, Leitman SF. Peripheral blood progenitor cells for HPC transplants involving unrelated donors. Transfusion 40:731-741, 2000.
  68. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane CL. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467-474, 2000.
  69. Lightfoot T, Leitman SF, Stroncek DF. Storage of granulocyte colony-stimulating-factor mobilized granulocyte concentrates. Transfusion 40:1104-1110, 2000.
  70. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FA, Zimmerman PA, Leitman SF, Detels R, Hajeer AH, Murphy PM. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS cohort Study. AIDS 14:2671-2678, 2000.
  71. McDermott DH, Colla JS, Kleeberger CA, Plankey M, Rosenberg PS, Smith ED, Zimmerman PA, Combadière C, Leitman SF, Kaslow RA, Goedert JJ, Berger EA, O'Brien TR, Murphy PM. Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 290:2031, 2000.
  72. Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Leitman SF, Read EJ, Carter CS, Wexler LH, Gress RE. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 96:754-62, 2000.
  73. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758, 2000.
  74. Smith JD, Leitman SF. Filtration of RBC unitseffect of storage time and temperature on filter performance. Transfusion 40:521-526; 2000.
  75. Lightfoot T, Gallelli J, Matsuo K, Kwon SW, Leitman SF, Stroncek DF. Evaluation of solutions for the storage of granulocyte colony-stimulating factor-mobilized granulocyte concentrates. Vox Sanguinis 2001 Feb; 80:106-111.
  76. Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001 Mar; 112:787-795.
  77. Horwitz ME, Barrett AJ, Holland SM, Childs R, Miller JA, Leitman SF, Read EJ, Carter CS, Brown MR, Gallin JI, Malech HL. Allogeneic stem cell transplantation for chronic granulomatous disease using low intensity marrow conditioning and T-cell depletion of the allograft. N Engl J Med 2001 Mar; 344:881-888.
  78. Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF. Sustained decreases in platelet count associated with multiple regular, plateletpheresis donations. Transfusion 2001 Jun; 41:756-761.
  79. Bolan CD, Conry-Cantilena C, Mason G, Rouault TA, Leitman SF. MCV as a guide to phlebotomy therapy for hereditary hemochromatosis. Transfusion 2001 Jun; 41:819-827.
  80. Stroncek DF, Procter JL, Moses L, Bolan CD, Pomper P, Conry-Cantilena C, Malech H, Leitman SF. Intravenous Rh immune globulin prevents alloimmunization in D-negative granulocyte recipients, but obscures the detection of an alloanti-K. Immunohematology 2001 Jun;17:37-41.
  81. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunotherapy 2001 Jul-Aug; 24:363-373.
  82. Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion 2001 Aug; 41:1037-1044.
  83. Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitman SF. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001 Sep; 41:1165-1171.
  84. Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001 Sep; 98:1687-1694.
  85. Kondo T, Cortese I, Markovic-Plese S, Wandinger KP, Carter C, Brown M, Leitman SF, Martin R. Dendritic cells signal T cells in the absence of exogenous antigen. Nature Immunol 2001 Oct; 2:932-938.
  86. Nakamura R, Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R, Dunbar CE, Gress R, Altemus R, Young NS, Barrett AJ. Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Brit J Haematol 2001 Oct; 115:95-104.
  87. Shi PA, Pomper GJ, Metzger ME, Donahue RE, Leitman SF, Dunbar CE. Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models. Transfusion 2001 Nov; 41:1438-1444.
  88. Bolan CD, Oral EA, Gorden P, Taylor S, Leitman SF. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab 2002 Jan; 87:380-384.
  89. Kang EM, de Witte M, Malech H, Morgan RA, Phang S, Carter C, Leitman SF, Childs R, Barrett AJ, Little R, Tisdale JF. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 2002 Jan 15; 99:698-701.
  90. Kang EM, Areman EA, David-Ocampo V, Fitzhugh C, Link ME, Read EJ, Leitman SF, Rodgers GP, Tisdale JF. Mobilization, collection and processing of peripheral blood progenitor cells in individuals with sickle cell trait. Blood 2002 Feb; 99:850-5.
  91. Dagher R, Long L, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TZ, Avila N, Berzovsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an interinstitute NIH study. Med Pediatr Oncol 2002 Mar; 38:158-164.
  92. Bolan CD, Leitman SF. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. Blood 2002 Mar; 99:1878.
  93. Stroncek DS, Matthews CL, Follman D, Leitman SF. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone . Transfusion 2002 May; 42:597-602.
  94. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Morton KE, Nahvi A, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunotherapy 2002 May-Jun; 25:243-251.
  95. Bolan CD, Cecco SA, Wesley RA, Horne M, Yau YY, Remaley AT, Childs RW, Barrett AJ, Rehak NN, Leitman SF. Controlled study of citrate effects and response to IV calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002 July; 42: 935-946.
  96. Kang EM, De Witte M, Malech H, Morgan RA, Carter C, Leitman SF, Childs R, Barrett AJ, Little R, Tisdale JF. Gene therapy-based treatment for HIV-positive patients with malignancies. J Hematother Stem Cell Res 2002 Oct; 11:809-16.
  97. Stroncek DF, Rainer T, Sharon V, Byrne KM, Noguchi CT, Klein HG, Schechter AN, Leitman SF. Sickle Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration. Transfusion 2002 Nov; 42:1466-72.
  98. Taylor JG, Tang DC, Savage SA, Leitman SF, Heller SI, Serjeant GR, Rodgers GP, Chanock SJ. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002 Dec 15; 100:4303-9.
  99. Bolan CD, Carter CS, Wesley RA, Yau YY, Barrett AJ, Childs RW, Read EJ, Leitman SF. Prospective evaluation of cell kinetics, yields and donor experiences during a single large volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. Brit J Hematol 2003 Mar; 120:801-807.
  100. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese M, Candotti F. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003 Apr; 101:2563-2569.
  101. Moncada V, Bolan CD, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003 Apr; 43:495-501.
  102. Solomon SR, Nakamura R, Read EJ, Leitman SF, Carter C, Childs R, Dunbar CE, Young NS, Barrett AJ. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003 May; 31:783-8.
  103. Stroncek D, Shawker T, Follmann D, Leitman SF. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003 May; 43:609-13.
  104. Byrne KM, Leitman SF, Schechter AN, Stroncek DF. Increasing oxygen tension improves filtration of sickle trait donor blood. Brit J Hematol 2003 Aug;122:678-81.
  105. Bolan CD, Wesley RA, Yau YY, Cecco SA, Starling J, Oblitas JM, Rehak NN, Leitman SF. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003 Oct; 43:1403-1413.
  106. Bolan CD, Cecco SA, Yau YY, Wesley RA, Oblitas JM, Rehak NN, Leitman SF. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 2003 Oct; 43:1414-1422.
  107. Pomper GJ, Rick ME, Epstein JS, Read EJ, Leitman SF. Management of severe von Willebrand's disease with cryoprecipitate collected by repeated apheresis of a single dedicated donor. Transfusion 2003 Nov;43:1514-21.
  108. Leitman SF, Browning JN, Yau YY, Mason G, Klein HG, Conry-Cantilena C, Bolan CD. Impact of using hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003 Nov; 43:1538-1544.
  109. Leitman SF, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, Boumpas DT, Illei GG. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus Transfusion 2003 Dec; 43:1667-1671.
  110. Moir S, Donoghue ET, Pickeral OK, Malaspina A, Planta MA, Chun TW, Krishnan SR, Kottilil S, Birse CE, Leitman SF, Fauci AS. Continuous flow leukapheresis induces expression of stress genes in lymphocytes; impact on microarray analyses. Blood 2003 Nov 15;102:3852-3.
  111. Bolan CD, Yau YY, Cullis HC, Horwitz ME, Mackall, CL, Barrett AJ, Malech HL, Rehak NN, Wayne AS, Leitman SF. Pediatric large volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. Transfusion 2004 Feb;44:229-238.
  112. Rick ME, Austin H, Leitman SF, Krizek DM, Aronson DL. Clinical usefulness of a functional assay for the von Willebrand Factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 2004 Feb;75:96-100.
  113. Yamashita K, Choi U, Woltz PC, Foster S, Sneller MC, Hakim F, Fowler D, Bishop M, Pavletic SZ, Tamari M , Castro K, Barrett AJ, Childs R, Illei G, Leitman SF, Malech HL, Horwitz M. Severe chronic graft-versus-host-disease is characterized by a preponderance of CD4+ effector memory cells relative to central memory cells. Blood 2004 May 15; 103:3986-8.
  114. Stroncek DF, Dittmar K, Shawker T, Heatherman A, Leitman SF. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Translational Med 2004 Jul; 2:25.
  115. Saif MW, Leitman SF, Cusack G, Horne M, Freifeld A, Venzon D, PremKumar A, Cowan, KH, Gress RE, Zujewski J, Kasten-Sportes C. Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer. Ann Oncol 2004 Sep; 15:1366-1372.
  116. Bishop MR, Steinberg SM, Gress R, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Castro K, Hakim F, Read EJ, Carter S, Leitman SF, Fowler DH. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Hematol 2004 Sep;126:837-843.
  117. Stroncek DF, Byrne KM, Noguchi CT, Schechter AN, Leitman SF. Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective leukocyte reduction by filtration. Transfusion 2004 Sep; 44:1293-99.
  118. Leitman SF, Bolan CD, Klein HG. Red cells from hemochromatosis donors. Marginalized, but hardly marginal. Letter. Transfusion 2004 Oct; 44:1537-38.
  119. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg S, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman SF, Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004 Oct; 22:3886-92.
  120. Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, Leitman SF, Bolan CD. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma. Transfusion 2004 Dec; 44:1679.
  121. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, Leitman SF, Finkel T, Cannon RO. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2005 Feb; 25:296-301.
  122. Griffith LM, McCoy JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF, Lundqvist A, Srinivasan R, Leitman SF, Childs RW. Persistence of recipient plasma cells and anti-donor isohemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005 Mar;128:668-75.
  123. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman SF, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett AJ. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005 Aug;106:1123-9.
  124. Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol. 2005 May;20:424-9.
  125. Tudisco C, Jett BW, Byrne K, Oblitas J, Leitman SF, Stroncek DF. The value of pH as a quality control indicator for apheresis platelets. Transfusion 2005 May;45:773-8.
  126. Pittman PR, Leitman SF, Barrera-Oro JG, Norris SL, Marano NM, Ranadive MV, Sink BS, McKee KT. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diag Lab Immunol 2005 Jun;12:713-21.
  127. Haddad S, Leitman SF, Wesley RA, Cecco S, Yau YY, Starling J, Rehak NN, Bolan CD. Randomized placebo-controlled study of intravenous magnesium supplementation during large volume leukapheresis in healthy allogeneic donors. Transfusion 2005 Jun;45:934-44.
  128. Patel HD, Byrne KM, Horne M, Leitman SF, Stroncek DF. Factors affecting the formation of white particulate matter in red blood cell components. Transfusion 2005 Jul;45:1127-32.
  129. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Metcalf JA, Davey R, Falloon J, Polis M, Tavel J, Stevens R, Fox S, Leitman SF, Baseler MW, Masur H, Dimitrov DS, Lane HC. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in patients with HIV infection. J Clin Invest 2005 Aug; 15:2139-48.
  130. Solomon SR, Savani BN, Childs R, Montero A, Boss C, Read EJ, Leitman SF, Barrett AJ.
    Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant 2005 Aug;11:619-26.
  131. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC. Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Therapy 2005 Sep;16:1065.
  132. Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, Solomon SR, Barrett AJ. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol 2005 Sep;130:733-9.
  133. Leitman SF. Progenitor cell mobilization gets a boost from CXCR4 inhibition. Blood 2005 Sep;106:1-2.
  134. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol. 2005 Nov; 46:1643-8.
  135. Stroncek D, Slezak S, Khuu H, Basil C, Tisdale J, Leitman SF, Marincola FM, Panelli MC. Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. Exp Hematol. 2005 Oct; 33:1109-17.
  136. Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant. 2006 Jan;12:22-30.
  137. Nambiar A, Duquesnoy R, Adams S, Zhao Y, Oblitas J, Leitman S, Stroncek D, Marincola F. HLA Matchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006 Feb 15;105:1680-1687.
  138. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, Leitman SF, Read EJ, Childs R, Barrett AJ. Factors associated with early molecular remission following T cell depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006 Feb 15;1688-1695.
  139. Stevens WT, Bolan CD, Oblitas JM, Bennett JE, Stroncek DF, Leitman SF. Streptococcus agalactiae sepsis following transfusion of a plateletpheresis concentrate: benefit of donor evaluation. Transfusion 2006 Apr;46:649-51.
  140. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Smith KP, Sachdev V, Birdsall CW, Sidenko S, Waclawiw MA, Leitman SF, Rosing DR. Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis. Am J Cardiol 2006 Sept;98:694-8.
  141. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Nguyen TT, Botello G, Sachdev V, Sidenko S, Ernst I, Waclawiw MA, Leitman SF, Rosing DR. Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. Am J Cardiol 2006 Oct; 98:954-9.
  142. Shizukuda Y, Bolan CD, Nugyen TT, Botello G, Tripodi DJ, Yau YY, Waclawiw MA, Leitman SF, Rosing RR. Oxidative stress in asymptomatic subjects with hereditary hemochromatosis. Am J Hematol 2006 Sep [Epub ahead of print].
  143. Ayache S, Panelli MC, Byrne KM, Slezak S, Leitman SF, Marincola FM, Stroncek DF. Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion. J Transl Med 2006 Oct 4;4:40.
  144. Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ. T-cell depleted peripheral blood stem cell allotransplantation with T cell add back for patients with hematological malignancies: effect of chronic GVHD on outcome for patients with hematological malignancies. Biol Blood Marrow Transplant 2006 Dec;12:1318-25.
  145. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Smith KP, Arena R, Waclawiw MA, Leitman SF, Rosing DR. Exercise capacity of cardiac asymptomatic hereditary hemochromatosis subjects. Med Sci Sports Exerc 2007 Jan; 39:3-7.
  146. Fadeyi EA, De Los Angeles Muniz M, Wayne AS, Klein HG, Leitman SF, Stroncek DF. The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion 2007 Mar;47:545-50.
  147. Allison RD, Bryant BJ, Vasu S, Leitman SF. Iron reduction and cardiovascular outcomes. J Am Med Assoc 2007 May; 297:2075 (letter).
  148. Arena R, Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Smith KP, Waclawiw MA, Leitman SF, Rosing DR. Heart rate recovery is lower following supine exercise in asymptomatic hereditary hemochromatosis subjects compared with healthy controls. J Cardiopulm Rehabil Prev 2007 Jun; 27:157-160.
  149. Provenzano M, Selleri S, Jin P, Wang E, Werden R, Slezak S, Adams SD, Panelli MC, Leitman SF, Stroncek DF, Marincola FM. Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. Cancer Immunol Immunother 2007 Jul; 56:1047-1063.
  150. Sloand EM, Read EJ, Scheinberg P, Tang Y, More K, Leitman SF, Maciejewski J, Young NS. Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients. Transfusion 2007 Jul;47:1250-1253.
  151. Bryant BJ, Bianchi M, Wesley RA, Stroncek DF, Leitman SF. Leukoreduction filtration of whole blood units from sickle trait donors: effects of a metered citrate anticoagulant system. Transfusion 2007 Aug (epub ahead of print).
  152. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007 Sep; 13:1096-1101.
  153. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chapters

  1. Leitman SF: Posttransfusion graft-versus-host disease. In: Smith DM and Silvergleid AJ (eds). Special considerations in transfusing the immunocompromised patient. American Association of Blood Banks, Arlington, VA p. 15-37, 1985.
  2. Leitman SF. Graft-versus-host disease and the role of blood product irradiation. In: Smit Sibinga CT, Das PC, Engelfriet CP (eds). Proceedings, 1lth Annual Symposium on Blood Transfusion: White cells and platelets in blood transfusion. Martinus Nijhoff, Boston, MA p.115-129, 1987.
  3. Leitman SF: The role of apheresis in the adoptive immunotherapy of cancer. In: Kasprisin DO, Westphal RG, eds. Current status of hemapheresis: Indications, technology, and complications. American Association of Blood Banks, Arlington, VA p.105-124, 1987.
  4. Leitman SF: Immunotherapy of cancer with lymphokine¬-activated killer cells: The role of transfusion medicine. In: Menitove JE, ed. Hematology 1987: Education Program of the American Society of Hematology. Grune & Stratton, New York, NY p. 39 -44, 1987.
  5. Leitman SF: Leukocyte inactivation by blood irradiation. In: Rossi EC, Simon TL, Moss GS, Gould SA, eds. Principles of Transfusion Medicine. Williams and Wilkins, Baltimore, MD, 1995.
  6. Leitman SF, Bolan CD: Hemochromatosis. In: Rodgers GP, Young NS, eds. Bethesda Handbook of Hematology. Lippincott Williams & Wilkins, Baltimore, MD. p. 361-372, 2004.
  7. Nambiar A, Leitman SF: Transfusion therapy. In: Boyiadzis MC, Lebowitz PF, Frame JN, Fojo T, eds. Hematology-Oncology therapy. McGraw-Hill, New York, NY. p. 607-630, 2006.

 
Updated: April 1, 2008